tiprankstipranks
Trending News
More News >
AnaptysBio Inc (ANAB)
NASDAQ:ANAB

AnaptysBio (ANAB) Stock Statistics & Valuation Metrics

Compare
654 Followers

Total Valuation

AnaptysBio has a market cap or net worth of $1.78B. The enterprise value is $1.77B.
Market Cap$1.78B
Enterprise Value$1.77B

Share Statistics

AnaptysBio has 28,748,255 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,748,255
Owned by Insiders
Owned by Institutions

Financial Efficiency

AnaptysBio’s return on equity (ROE) is -0.36 and return on invested capital (ROIC) is 14.61%.
Return on Equity (ROE)-0.36
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)14.61%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee1.73M
Profits Per Employee364.81K
Employee Count136
Asset Turnover0.64
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of AnaptysBio is ―. AnaptysBio’s PEG ratio is 1.12.
PE Ratio
PS Ratio5.74
PB Ratio36.21
Price to Fair Value36.21
Price to FCF68.70
Price to Operating Cash Flow87.49
PEG Ratio1.12

Income Statement

In the last 12 months, AnaptysBio had revenue of 234.60M and earned -13.23M in profits. Earnings per share was -0.46.
Revenue234.60M
Gross Profit232.18M
Operating Income47.90M
Pretax Income-13.07M
Net Income-13.23M
EBITDA50.32M
Earnings Per Share (EPS)-0.46

Cash Flow

In the last 12 months, operating cash flow was 19.70M and capital expenditures -87.00K, giving a free cash flow of 19.61M billion.
Operating Cash Flow19.70M
Free Cash Flow19.61M
Free Cash Flow per Share0.68

Dividends & Yields

AnaptysBio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.82
52-Week Price Change250.14%
50-Day Moving Average50.52
200-Day Moving Average34.25
Relative Strength Index (RSI)61.86
Average Volume (3m)451.66K

Important Dates

AnaptysBio upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 3, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date

Financial Position

AnaptysBio as a current ratio of 9.07, with Debt / Equity ratio of 781.08%
Current Ratio9.07
Quick Ratio9.07
Debt to Market Cap0.01
Net Debt to EBITDA-4.45
Interest Coverage Ratio0.60

Taxes

In the past 12 months, AnaptysBio has paid 164.00K in taxes.
Income Tax164.00K
Effective Tax Rate-0.01

Enterprise Valuation

AnaptysBio EV to EBITDA ratio is 22.32, with an EV/FCF ratio of 57.27.
EV to Sales4.79
EV to EBITDA22.32
EV to Free Cash Flow57.27
EV to Operating Cash Flow57.02

Balance Sheet

AnaptysBio has $311.64M in cash and marketable securities with $290.64M in debt, giving a net cash position of $21.00M billion.
Cash & Marketable Securities$311.64M
Total Debt$290.64M
Net Cash$21.00M
Net Cash Per Share$0.73
Tangible Book Value Per Share$1.34

Margins

Gross margin is 98.97%, with operating margin of 20.42%, and net profit margin of -5.64%.
Gross Margin98.97%
Operating Margin20.42%
Pretax Margin-5.57%
Net Profit Margin-5.64%
EBITDA Margin21.45%
EBIT Margin20.42%

Analyst Forecast

The average price target for AnaptysBio is $81.57, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$81.57
Price Target Upside36.63% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast196.42%
EPS Growth Forecast53.92%

Scores

Smart Score10
AI Score